The KEYNOTE-059 study found that pembrolizumab demonstrated a durable effect on OS/PFS in multilined-treated advanced GC patients, showed durable antitumor activity, and had a manageable safety profile, especially in patients with high PD-L1 expression and MSI-H (46). Here, CD274 is linked to gastric cancer.